[{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"IMM60","moa":"iNKT","graph1":"Oncology","graph2":"Phase I","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Portage Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Portage Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"IMM60","moa":"iNKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Portage Biotech \/ University of Oxford","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ University of Oxford"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Portage Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"IMM60","moa":"iNKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Portage Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Stimunity","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Virus Like Particles","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Stimunity","highestDevelopmentStatusID":"4","companyTruncated":"Portage Biotech \/ Stimunity"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM60","moa":"iNKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"STI-001","moa":"STING","graph1":"Oncology","graph2":"Preclinical","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Portage Biotech \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Portage Biotech \/ National Cancer Institute"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM60","moa":"iNKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Portage Biotech \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Intensity Therapeutics"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Tarus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"PORT-6","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Portage Biotech \/ Portage Biotech Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Portage Biotech Inc."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Tarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TT-10","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Tarus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Tarus Therapeutics"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"IMM60","moa":"iNKT","graph1":"Oncology","graph2":"Preclinical","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Portage Biotech \/ Merck"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TT-10","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"TT-10","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Merck & co","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Merck & co"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"TT-10","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Portage Biotech \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ H.C. Wainwright & Co."}]

Find Clinical Drug Pipeline Developments & Deals by Portage Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The Company intends to use the net proceeds for clinical development of TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors.

                          Brand Name : TT-10

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 29, 2023

                          Lead Product(s) : TT-10

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : H.C. Wainwright & Co.

                          Deal Size : $6.0 million

                          Deal Type : Public Offering

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Under theagreement, Merck will provide KEYTRUDA for Portage's Phase 1a/1b trial evaluating adenosine 2A receptor antagonist candidate, TT-10 in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.

                          Brand Name : TT-10

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 05, 2023

                          Lead Product(s) : TT-10,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : TT-10 is an orally administered Portage’s adenosine 2A receptor (A2AR) antagonist candidate evaluating in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.

                          Brand Name : TT-10

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 26, 2023

                          Lead Product(s) : TT-10

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Under the terms of the agreement, Merck will be providing KEYTRUDA for Portage Biotech’s IMPORT-201 trial, a Phase 1/2 study of PORT-2, a liposomal formulation of IMM60, for patients with NSCLC and advanced melanoma (also known as KEYNOTE E69).

                          Brand Name : IMM60

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 08, 2022

                          Lead Product(s) : IMM60,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR) in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents.

                          Brand Name : TT-10

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 14, 2022

                          Lead Product(s) : TT-10

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Tarus Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : As a result of the transaction, Portage acquires four best-in-class assets including TT-10/PORT-6, targeting different aspects of the adenosine pathway, and is now in a unique position to evaluate the role of adenosine in cancer and other diseases.

                          Brand Name : TT-10

                          Molecule Type : Small molecule

                          Upfront Cash : $21.0 million

                          July 06, 2022

                          Lead Product(s) : PORT-6

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Tarus Therapeutics

                          Deal Size : $53.0 million

                          Deal Type : Acquisition

                          blank

                          07

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Translational analysis of IMM60 confirms that PORT-2 activates iNKT cells, NK cells and dendritic cells, supporting the mechanism of action to stimulate both the adaptive and innate immune system.

                          Brand Name : IMM60

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 06, 2022

                          Lead Product(s) : IMM60,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Intensity Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Portage, Stimunity and NCI will collaborate with Center for Cancer Research to advance preclinical and clinical development of STING agonists, STI-001 and anti-Receptor for Advanced Glycation End products agents, for possible synergy to enhance the effic...

                          Brand Name : STI-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 25, 2022

                          Lead Product(s) : STI-001,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : National Cancer Institute

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Clinical trials were initiated in 2021 for both of Portage’s lead invariant natural killer T cell (iNKT) agonist programs, PORT-2 (a liposomal formulation iNKT agonist) and PORT-3 (a nanoparticle coformulation of Portage’s iNKT agonist packaged with ...

                          Brand Name : IMM60

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 31, 2022

                          Lead Product(s) : IMM60,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : PORT-5 (STI-001), offers a potentially first-in-class approach to developing molecules that activate the STING pathway by packaging a STING agonist in a virus-like particle (VLP), a well-tested delivery system that can be customized and targeted to speci...

                          Brand Name : PORT-5

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 09, 2022

                          Lead Product(s) : Virus Like Particles

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Stimunity

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank